I'd say that ISG, Information Services Group, Inc. (NASDAQ: III ) is in an interesting phase right now. Margins are growing, we have recurring revenue on the rise, and there's a lot of promise within the AI-assisted advisory market. At the same time, though, theI’m Emmanuel Onwusah—a financial analyst, writer, and recovering engineer. I hold FMVA® and BIDA® certifications from the Corporate Finance Institute, and I spend most of my time creating pitch decks, building models, analyzing companies, and trying ...

Core Viewpoint - Intuitive has successfully demonstrated its telesurgery capabilities by connecting two surgeons remotely to perform a transatlantic surgery at the Society of Robotic Surgery conference, showcasing advancements in robotic-assisted surgery technology [1][2][4]. Company Overview - Intuitive, headquartered in Sunnyvale, California, is a leader in minimally invasive care and robotic surgery, with a focus on improving patient outcomes and care delivery efficiency [11]. - The company has developed the da Vinci surgical system, which has been used in nearly 17 million procedures over 30 years, training almost 90,000 surgeons [8]. Telesurgery Demonstration - The demonstration involved Dr. Doug Stoddard in Georgia and Dr. Andrea Pakula in France, using a dual console da Vinci 5 system to perform surgery on an advanced tissue model [2][3]. - The surgeons were able to exchange control of surgical instruments remotely, utilizing Force Feedback technology to simulate the sensation of operating on live tissue despite being over 4,000 miles apart [3]. Future of Telesurgery - Intuitive's CEO emphasized the potential of telesurgery to enhance patient access to care, while also noting the importance of careful development in infrastructure and technology to ensure safety and reliability [4][6]. - The company is focused on building a robust network infrastructure to support telesurgery, rather than being the first to market [7]. Technology Development - The telesurgery software demonstrated is still in development and not yet cleared for sale or use in the U.S. or EU, indicating ongoing efforts to ensure safety and effectiveness [9]. - Intuitive's telecollaboration suite includes telementoring and teleproctoring, aimed at improving clinical outcomes and reducing care costs [6].

Key Takeaways FTI won a significant iEPCI contract from Equinor for the Heidrun extension in the Norwegian North Sea. The award followed a successful iFEED phase that optimized field layout and minimized lifecycle costs. The project supports Heidrun's long-term output while reducing environmental impact and capital expenditure.TechnipFMC plc (FTI) , a Houston, TX-based oil and gas equipment and services company, has been awarded a significant integrated Engineering, Procurement, Construction, and Installa ...

ETF inflow numbers so far this week 📝Monday: BTC has $297M, ETH has $259MTuesday: BTC has $403M, ETH has $192MOverall $700M for BTC and $450M for ETHETH flows massively outperforming right now on market-cap weighted basis ...

Resilient performance through volatile environmentSAN FRANCISCO, July 16, 2025 /PRNewswire/ -- Prologis, Inc. (NYSE: PLD) today announced the following results for the quarter ended June 30, 2025, as compared to the corresponding period in 2024: Net earnings per diluted share was $0.61 and decreased 33.7% due to lower gains and unrealized FX. Core funds from operations (Core FFO)* per diluted share was $1.46 and increased 9.0%. Core FFO, excluding Net Promote Income (Expense)* per diluted share was $1.47 an ...

Core Insights - Madrigal Pharmaceuticals has received a Notice of Allowance from the USPTO for Rezdiffra™, the first FDA-approved treatment for adults with noncirrhotic MASH with moderate to advanced liver fibrosis [1][2] - The patent protection for Rezdiffra is set to last until September 30, 2044, and will be included in the FDA's Orange Book [2] - The CEO of Madrigal emphasized that this milestone supports the company's long-term strategy for Rezdiffra and highlights the significance of their clinical development program [3] Company Overview - Madrigal Pharmaceuticals focuses on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with significant unmet medical needs [3] - Rezdiffra (resmetirom) is a once-daily oral THR-β agonist aimed at addressing the underlying causes of MASH, specifically approved for patients with moderate to advanced fibrosis (F2 to F3 stages) [3] - An ongoing Phase 3 trial is assessing Rezdiffra for the treatment of compensated MASH cirrhosis (F4c stage) [3]

Core Insights - The Invesco Russell 2000 Dynamic Multifactor ETF (OMFS) offers investors broad exposure to the small-cap blend market segment, having debuted on November 8, 2017 [1] - The ETF industry has been traditionally dominated by market capitalization weighted indexes, but smart beta strategies are gaining traction among investors seeking to outperform the market through stock selection [2][3] Fund Overview - Managed by Invesco, OMFS has accumulated over $239.4 million in assets, positioning it as an average-sized ETF within its category [5] - The fund aims to match the performance of the Russell 2000 Invesco Dynamic Multifactor Index, which selects stocks from the Russell 2000 Index, representing 2,000 small-cap companies in the U.S. [6] Cost Structure - OMFS has an annual operating expense ratio of 0.39%, which is competitive within its peer group, and a 12-month trailing dividend yield of 1.30% [7] Sector Allocation and Holdings - The fund's largest sector allocation is to Financials at 28.1%, followed by Industrials and Information Technology [8] - Sprouts Farmers Market Inc (SFM) is the largest individual holding at 3.44% of total assets, with the top 10 holdings comprising approximately 14.19% of OMFS's total assets [9] Performance Metrics - Year-to-date, OMFS has returned approximately 2.13% and is up about 8.98% over the last 12 months as of July 16, 2025 [11] - The fund has a beta of 1.05 and a standard deviation of 21.10% over the trailing three-year period, indicating effective diversification with around 649 holdings [11] Alternatives - Investors seeking to outperform the small-cap blend segment may consider OMFS, but there are alternative ETFs such as iShares Russell 2000 ETF (IWM) and iShares Core S&P Small-Cap ETF (IJR) that may offer lower expense ratios and risk profiles [12][13]

Core Viewpoint - The SPDR MSCI USA StrategicFactors ETF (QUS) is a smart beta ETF that aims to provide broad exposure to the large-cap blend market segment, with a focus on outperforming traditional market cap weighted indexes [1][5]. Fund Overview - Launched on April 15, 2015, QUS has accumulated over $1.55 billion in assets, positioning it as one of the larger ETFs in its category [1][5]. - The fund is sponsored by State Street Global Advisors and seeks to match the performance of the MSCI USA Factor Mix A-Series Index [5]. Cost Structure - QUS has an annual operating expense ratio of 0.15%, making it one of the cheaper options in the smart beta ETF space [6]. - The fund's 12-month trailing dividend yield is 1.44% [6]. Sector Exposure and Holdings - The largest sector allocation for QUS is Information Technology, comprising approximately 25.1% of the portfolio, followed by Financials and Healthcare [7]. - Microsoft Corp (MSFT) is the top holding at about 3.22% of total assets, with Apple Inc (AAPL) and Nvidia Corp (NVDA) also among the top positions. The top 10 holdings account for about 21.39% of total assets [8]. Performance Metrics - As of July 16, 2025, QUS has gained approximately 5.3% year-to-date and 8.73% over the past year [9]. - The fund has traded between $140.84 and $164.55 in the last 52 weeks [9]. Risk Profile - QUS has a beta of 0.88 and a standard deviation of 14.33% over the trailing three-year period, indicating a medium risk profile [10]. - The fund holds about 552 securities, which helps to diversify company-specific risk [10]. Alternatives - Other ETFs in the large-cap blend space include SPDR S&P 500 ETF (SPY) and Vanguard S&P 500 ETF (VOO), with assets of $639.29 billion and $688.86 billion respectively. SPY has an expense ratio of 0.09% and VOO charges 0.03% [11].

Core Insights - The Vanguard Dividend Appreciation ETF (VIG) is a smart beta ETF launched on April 21, 2006, providing broad exposure to the large-cap blend market segment [1] - VIG aims to match the performance of the NASDAQ US Dividend Achievers Select Index, focusing on companies with a history of increasing dividends [5] Fund Overview - VIG has amassed over $92.31 billion in assets, making it one of the largest ETFs in its category [5] - The ETF has an annual operating expense ratio of 0.05%, positioning it as one of the least expensive options available [6] - The 12-month trailing dividend yield for VIG is 1.72% [6] Sector Exposure and Holdings - The ETF has a significant allocation in the Information Technology sector, comprising approximately 25.9% of the portfolio, followed by Financials and Healthcare [7] - Broadcom Inc (AVGO) represents about 5.11% of the fund's total assets, with Microsoft Corp (MSFT) and Jpmorgan Chase & Co (JPM) also among the top holdings [8] Performance Metrics - VIG has increased by roughly 5.27% year-to-date and has risen about 10.67% over the past year as of July 16, 2025 [9] - The ETF has traded between $173.71 and $207.81 in the past 52 weeks [9] - VIG has a beta of 0.85 and a standard deviation of 14.24% over the trailing three-year period, indicating a medium risk profile [10] Alternatives - Other ETFs in the same space include WisdomTree U.S. Quality Dividend Growth ETF (DGRW) and iShares Core Dividend Growth ETF (DGRO), with assets of $15.95 billion and $32.19 billion respectively [12] - DGRW has an expense ratio of 0.28%, while DGRO has a lower expense ratio of 0.08% [12]

Core Viewpoint - The Invesco S&P SmallCap 600 Pure Value ETF (RZV) offers investors exposure to small-cap value stocks and aims to match the performance of the S&P SmallCap 600 Pure Value Index, with a focus on strong value characteristics [1][5]. Fund Overview - RZV debuted on March 1, 2006, and has accumulated over $209.5 million in assets, categorizing it as an average-sized ETF in the small-cap value space [1][5]. - The fund is sponsored by Invesco and has an annual operating expense ratio of 0.35%, which is competitive within its peer group [5][6]. Performance Metrics - Year-to-date, RZV has experienced a loss of approximately -2.68%, while it has gained about 4.65% over the last 12 months as of July 16, 2025 [9]. - The ETF has a beta of 1.20 and a standard deviation of 24.59% over the trailing three-year period, indicating a higher risk profile [10]. Sector Allocation - The fund's largest sector allocation is in Consumer Discretionary, comprising about 26.9% of the portfolio, followed by Financials and Energy [7]. - Par Pacific Holdings Inc (PARR) is the largest individual holding at approximately 2.49% of total assets, with the top 10 holdings accounting for about 17.72% of RZV's total assets [8]. Alternatives - Other ETFs in the small-cap value space include iShares Russell 2000 Value ETF (IWN) and Vanguard Small-Cap Value ETF (VBR), which have significantly larger asset bases of $10.87 billion and $29.86 billion, respectively [12]. - IWN has a lower expense ratio of 0.24%, while VBR has a minimal change of 0.07%, making them potentially more attractive options for cost-conscious investors [12].